0001209191-23-043997.txt : 20230801 0001209191-23-043997.hdr.sgml : 20230801 20230801163510 ACCESSION NUMBER: 0001209191-23-043997 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230728 FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McClellan William D. Jr. CENTRAL INDEX KEY: 0001689402 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37785 FILM NUMBER: 231132298 MAIL ADDRESS: STREET 1: C/O APOLLO ENDOSURGERY, INC., 1120 S. STREET 2: CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REATA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001358762 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113651945 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5320 LEGACY DRIVE CITY: PLANO STATE: TX ZIP: 75024 BUSINESS PHONE: 972-865-2219 MAIL ADDRESS: STREET 1: 5320 LEGACY DRIVE CITY: PLANO STATE: TX ZIP: 75024 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-28 0 0001358762 REATA PHARMACEUTICALS INC RETA 0001689402 McClellan William D. Jr. 5320 LEGACY DRIVE PLANO TX 75024 1 0 0 0 1 Class A common stock 2023-07-28 4 C 0 5000 A 11017 D Class A common stock 2023-07-28 4 S 0 5000 164.4883 D 6017 D Stock Option (right to buy) 26.46 2023-07-28 4 M 0 5000 0.00 D 2027-03-01 Class B common stock 5000 4500 D Class B common stock 2023-07-28 4 M 0 5000 26.46 A Class A common stock 5000 5000 D Class B common stock 2023-07-28 4 C 0 5000 D Class A common stock 5000 0 D The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date. The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $164.69. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The options vested in three equal installments on March 1, 2018, March 1, 2019 and March 1, 2020. /s/ Tracy Herson, attorney-in-fact 2023-08-01